Logo

Predicant Biosciences Obtains $7.5M Debt Financing to Develop Protein Biomarker Technology

Oct 11, 2005

NEW YORK, Oct. 11 (GenomeWeb News) - Predicant Biosciences has received $7.5 million in debt financing from Hercules Technology Growth Capital, the Palo Alto-based specialty finance company said today.

 

Predicant will use the financing to develop and market protein biomarker technology for diagnostic tests.

 

The company, based in South San Francisco, Calif., has been developing separation, detection, and informatics technologies for identifying and assaying protein biomarkers for use in diagnostics and drug development.

Breaking News
The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.